Cargando…

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth

Gastrointestinal stromal tumors (GISTs) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most GISTs contain oncogenic KIT (85%) or PDGFRA (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serrano‐Candelas, Eva, Ainsua‐Enrich, Erola, Navinés‐Ferrer, Arnau, Rodrigues, Paulo, García‐Valverde, Alfonso, Bazzocco, Sarah, Macaya, Irati, Arribas, Joaquín, Serrano, César, Sayós, Joan, Arango, Diego, Martin, Margarita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068349/ https://www.ncbi.nlm.nih.gov/pubmed/29885053 http://dx.doi.org/10.1002/1878-0261.12332

Ejemplares similares

Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration
por: Navinés-Ferrer, Arnau, et al.
Publicado: (2019)

SH3BP2 Silencing Increases miRNAs Targeting ETV1 and Microphthalmia-Associated Transcription Factor, Decreasing the Proliferation of Gastrointestinal Stromal Tumors
por: Proaño-Pérez, Elizabeth, et al.
Publicado: (2022)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments
por: Navinés-Ferrer, Arnau, et al.
Publicado: (2016)

Prostaglandin E(2) Prevents Hyperosmolar-Induced Human Mast Cell Activation through Prostanoid Receptors EP(2) and EP(4)
por: Torres-Atencio, Ivonne, et al.
Publicado: (2014)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia
por: Navinés-Ferrer, Arnau, et al.
Publicado: (2018)

Author Correction: MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia
por: Navinés-Ferrer, Arnau, et al.
Publicado: (2021)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA
por: Terada, Tadashi
Publicado: (2012)

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations
por: Eliyakin, Nuket, et al.
Publicado: (2015)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
por: Carlotto, Bianca Soares, et al.
Publicado: (2023)

IRF4-dependent dendritic cells regulate CD8(+) T cell differentiation and memory responses in influenza infection
por: Ainsua-Enrich, Erola, et al.
Publicado: (2019)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
por: Baskin, Yasemin, et al.
Publicado: (2016)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Long-term cigarette smoke exposure dysregulates pulmonary T cell response and IFN-γ protection to influenza virus in mouse
por: Wu, Wenxin, et al.
Publicado: (2021)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Disruption of c-Kit Signaling in Kit(W-sh/W-sh) Growing Mice Increases Bone Turnover
por: Lotinun, Sutada, et al.
Publicado: (2016)

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
por: Rizzo, Francesca Maria, et al.
Publicado: (2016)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

A Malignant Gastrointestinal Stromal Tumor of the Gallbladder Immunoreactive for PDGFRA and Negative for CD 117 Antigen (c-KIT)
por: Petrou, Athanasios, et al.
Publicado: (2011)

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA
por: Beadling, Carol, et al.
Publicado: (2013)

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7kglecq0rlkbjuvs47q28p748